Capstan Medical Completes First U.S. Procedure With Investigational Robotic Mitral Valve Replacement System

PR News WireThis post was originally published on this site

Share this story

Transcatheter procedure performed at The Christ Hospital using the Capstan Compass Robotic System

SANTA CRUZ, Calif., Nov. 16, 2026 /PRNewswire/ — CAPSTAN MEDICAL® today announced the successful completion of its first U.S. robot-assisted transcatheter mitral valve replacement (TMVR) procedure. This marks an important advancement in developing its robotic-enabled, minimally invasive technology to treat heart valve disease.

The procedure was performed November 9 at The Christ Hospital in Cincinnati, Ohio, by a team led by Santiago Garcia, MD, Director of the Structural Heart Program. The procedure was conducted as part of a U.S. Food and Drug Administration (FDA)-authorized early feasibility study.

“This first U.S. procedure represents another significant step forward in the treatment of structural heart disease. I am pleased to report that the procedure was successful, and the patient was discharged home in stable condition,” said Dr. Garcia. “The robotic platform is designed to provide catheter stability and control, enabling precise positioning of the mitral valve implant. This technology has the potential to fundamentally change what is possible for patients who cannot undergo conventional heart surgery, which remains an important unmet clinical need.”

Mitral regurgitation occurs when the mitral valve does not close properly, allowing blood to flow backward through the heart. Many patients are too high-risk for conventional surgery and the existing catheter-based treatments are not suitable for all patients.

Capstan’s investigational TMVR technology combines a flexible, multi-axis catheter, robotic navigation and a novel valve implant. Designed to treat a greater number of mitral valve patients and overcome the challenges of navigating the heart’s complex anatomy. The system gives physicians precise control over catheter movement, valve positioning and deployment during minimally invasive procedures.

In lieu of managing multiple knobs on a traditional catheter systems, the Capstan System enables physicians to perform the TMVR procedure via inputs from a handheld controller with precise control over catheter movement, valve positioning and deployment.

“This first U.S. case builds on our initial clinical experience and brings us another step closer to expanding treatment options to patients who need them most.” said Maggie Nixon, Chief Executive Officer of Capstan Medical. “The Capstan technology lays the foundation for what heart valve intervention should be; simple, reproducible and low-stress. We couldn’t be more excited for this milestone that makes that future a reality.” The milestone follows Capstan’s pioneering first-in-human robotic-assisted mitral valve replacement procedures, completed in Chile and announced in March 2025. Dr. Garcia was also present in those procedures.

About Capstan Medical

Founded in 2020, Capstan Medical is creating a new standard for minimally invasive heart valve intervention. The company is developing a suite of next-generation heart valve implants and a first-of-its-kind catheter-based robotic delivery platform designed to expand treatment options for patients with structural heart disease. For more information, visit www.capstanmedical.com.

The Capstan Compass TMVR system is investigational and is not approved for commercial use in the United States.

SOURCE Capstan

Leave a Comment

Your email address will not be published. Required fields are marked *

*